Addressing Unmet Needs With Gene Therapy


Eric Crombez, PhD, senior vice president and chief medical officer of Ultragenyx Gene Therapy, discussed indications the company is targeting.

“We've really tried to focus on diseases... with a high unmet medical need... and with the highest likelihood of success. With the broad platform modalities we have built within Ultragenyx, with small molecules, enzyme replacement therapy, gene therapy, and more recently messenger RNA, we can really focus in on these diseases... with high unmet medical need... and then choose which modality is the best way to take on these diseases.”

Ultragenyx Gene Therapy, part of Ultragenyx Pharmaceuticals, is targeting diseases with high unmet medical needs for their gene therapy development program. They are exploring adeno-associated virus vector (AAV)-directed gene therapy in indications such as glycogen storage disease (GSD), ornithine transcarbamylase (OTC) deficiency, Wilson disease, and Duchenne muscular dystrophy (DMD).

Their lead programs are phase 3 studies of DTX401 for the treatment of GSD type 1a (NCT03517085) and DTX301 for the treatment of OTC deficiency (NCT02991144). UX053, an mRNA therapy, also recently received orphan drug designation for the potential treatment of GSD type 3 and will be evaluated in a phase 1/2 trial beginning enrollment in the second half of 2021.

GeneTherapyLive spoke with Eric Crombez, MD, senior vice president and chief medical officer, Ultragenyx Gene Therapy, to learn more about the indications the company has chosen to target. He also discussed the HeLa platform that their DMD program will be using and the company’s discussions with the FDA.

Ultragenyx receives Orphan Drug Designation from FDA and European Commission for UX053, an investigational mRNA-therapy for the treatment of Glycogen Storage Disease Type III. News release. Ultragenyx Pharmaceuticals. July 27, 2021.
Related Videos
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
© 2024 MJH Life Sciences

All rights reserved.